📰 Adapted News
Page 4 - Adapted News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adapted. Real-time updates on events, politics, business and more.
January 5, 2023
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum Trial size to be adapted upon interim analysis with planned total patient number... | January 5, 2023
December 25, 2022
BioNTech and its partner for China, Shanghai Fosun Pharmaceutical, were granted approval for their COVID-19 vaccine that is adapted for the BA.4 and the BA.5 subvariants of Omicron for people aged... | December 24, 2022
December 19, 2022
SINGAPORE, Nov. 4, 2022 /PRNewswire/ --ThitsaWorks, in partnership with INFITX (previously ModusBox) and Visa, was awarded the Monetary Authority of Singapore's Financial Sector Technology and Innovation (FSTI) Proof of Concept (POC) grant on 29-June-2022. The FSTI POC grant supports the experimentation, development, and dissemination of nascent innovative technologies in the financial services sector. While many remittance options exist for overseas migrant workers in Singapore, options to ...
December 8, 2022
Bivalent vaccine authorized as third 3-µg dose in the three-dose primary seriesConsistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children
December 8, 2022
Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series Consistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses
November 18, 2022
One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to
November 10, 2022
NEW YORK and MAINZ, GERMANY, November 10, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY Original/Omicron BA.4/BA.5
November 4, 2022
Bivalent booster elicited approximately 4-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine in individuals older than 55 years
November 4, 2022
NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) and German partner BioNTech SE (BNTX) announced Friday updated data from a Phase 2/3 clinical trial for Omicron BA.4/BA.5-adapted bivalent
November 2, 2022
EMA’s human medicines committee (CHMP) has recommended authorising an adapted Spikevax COVID-19 vaccine targeting the Omicron subvariants BA.4 and...